Skip to content

Diagnosis and Treatment Status and Medical Burden of Respiratory Syncytial Virus Infection in Children in China

Beijing Children's Hospital, Capital Medical University, China National Clinical Research Center of Respiratory Diseases, National Center for Children's Health, Beijing, China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07264478
Enrollment
1100
Registered
2025-12-04
Start date
2022-10-15
Completion date
2025-12-30
Last updated
2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disease Burden, RSV Infection

Brief summary

To understand the diagnosis and treatment status and medical burden of respiratory syncytial virus (RSV) infection in children in China, and to provide scientific basis for formulating prevention and treatment strategies for children. According to the seven administrative regions of China, namely Northeast, North, Northwest, Southwest, Central, South and East China, 1-3 children's medical institutions were selected from each region, and the cases of bronchiolitis or pneumonia admitted to hospitals and diagnosed as RSV positive by etiology during January 1, 2017 to December 31, 2021 were selected. Demographic data and clinical information were collected, and subgroup analysis was designed to explore the relationship between them and medical expenses and clinical treatment burden.

Interventions

OTHERuninvolved

uninvolved

Sponsors

Beijing Children's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

Hospitalized patients under 18 years of age with an etiological diagnosis of RSV-positive bronchiolitis or pneumonia

Exclusion criteria

Inpatients under 18 years of age with an etiological diagnosis of RSV-positive bronchiolitis or pneumonia are excluded from any of the following criteria: 1. Pneumonia occurring 48 hours after hospitalization; 2. Combined with bronchial foreign body; 3. Participants in clinical trials of drugs or medical devices; 4. Not complete personal and family history and other relevant information.

Design outcomes

Primary

MeasureTime frameDescription
hospitalization costsduration of hospital stayhospitalization costs,pharmcost,testcost,testcost

Secondary

MeasureTime frameDescription
hospital dayduration of hospital stayduration of hospital stay

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026